MaxCyte Q2 EPS $(0.10), Inline, Sales $9.04M Miss $10.80M Estimate
Portfolio Pulse from sunil@benzinga.com
MaxCyte (NASDAQ:MXCT) reported Q2 losses of $(0.10) per share, meeting analyst consensus. This is a 25% decrease from the same period last year. Quarterly sales were $9.04M, missing the analyst consensus of $10.80M by 16.27%, a 5.88% decrease from last year.
August 09, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
MaxCyte's Q2 earnings met analyst expectations but sales missed estimates. This could potentially impact the stock negatively in the short term.
MaxCyte's earnings per share met analyst expectations, which is a positive signal. However, the company's sales missed the consensus estimate by 16.27%, which is a significant miss and could lead to a negative reaction in the stock market. Additionally, both earnings and sales decreased compared to the same period last year, which could further negatively impact investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100